# SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

> **NCT05020769** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SI-B001
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05020769
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-06
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020769, "SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05020769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*